Daniel Grau is an experienced biopharma entrepreneur and operating executive. He currently serves as CEO, President, and Director at Avilar Therapeutics, a leading extracellular protein degradation company, and as an advisor at HotSpot Therapeutics. Mr. Grau’s previous roles include CEO at Sojournix, President at Heptares Therapeutics (acquired 2015), CEO at Cortria (acquired 2010), and COO at CombinatoRx (IPO 2005), Board Director at Research Alliance Corporation I (merged with POINT Biopharma), Board Director at TetraGenetics (acquired by AbCellera), advisor at RA Ventures, member of the Product Advisory Board at Concert Pharmaceuticals, and advisor to Nimbus Therapeutics. Early in his career, Mr. Grau worked with Pharmacia, Pharmacia & Upjohn, and Eisai as a management consultant focused on corporate strategy, M&A, and new product commercialization. Prior to management consulting, Mr. Grau was Director of Marketing & Business Development at a clinical information technology startup. Mr. Grau earned his BA with High Honors from Davidson College, where he was awarded a Dana Honor Scholarship and elected to Phi Beta Kappa, and his MPhil, MA, and MAR degrees from Yale University, where he was awarded the Day Graduate Prize and was the recipient of a Mellon Fellowship in the Humanities.
